FDA Plans To Use Third Parties To Review LDTs

The FDA expects that outside reviewers will be able to handle about half of all lab-developed test submissions, a spokesman told Medtech Insight. Meanwhile, a recent CDRH memo discussing COVID-19 test validation offers further background on why the agency is concerned about LDT accuracy and reliability.